FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963955499> ?p ?o ?g. }

• W1963955499 abstract "Background The use of drugs with active ingredients produced through genetic engineering is often associated with oncology, rheumatology, dermatology and gastroenterology treatment although today there is wider use in cardiology (canakimumab) for certain products for the treatment of ocular pathologies, with particular reference to the retinal pathologies. Currently the active principles used in ophthalmology are ranibizumab, pegaptanib and bevacizumab. The first two active ingredients are marketed in syringes ready for intravitreal use, but bevacizumab does not have a formulation different from that for use in oncology. Ranibizumab is a fragment derived from the immunised antibody bevacizumab that exerts its anti-neogenic and vascular permeability-reducing actions by blocking VEGF (endothelial growth factors) with particular reference to isoforms VEGF165, VEGF121 and VEGF110. It is able to penetrate all the layers of the retina and enter the subretinal space. Purpose To evaluate the economic impact of anti-VEGF drugs on the budget of the ophthalmology department and the average cost of treatment with ranibizumab considering a series of patients treated for age-related macular degeneration (AMD) at the Ophthalmology department in the Paolo Giaccone Hospital, Palermo. Materials and Methods The consumption data were obtained from the accounting system of the integrated Polyclinic company, data on doses were obtained from a selection of patients who have had treatment from one to four years, and data were extracted from the AIFA monitoring log for ophthalmic medicines. Results During the years 2007 to 2011 the share of the budget absorbed by anti-VEGF increased from €58,375.1 (45% of annual expenditure) to 246,592.71 (84% of expenditure). Given that the administration characteristics cannot be standardised we recorded the number of administrations for the patients treated. 8 patients that have been identified for a year’s treatment received 3 to 4 administrations at an average cost per patient of Euro 4,023.25. 19 patients were treated for 2 years with average spending Euro 6,776 (4–9 doses) and a total cost 128,774 euros. 8 patients were treated for 3 years, average Euro 10,201.81 (6–13 doses) total expenditure Euro 81,614.5; Finally 5 patients were treated for 4 years, average Euro 13,334.2 (9–17 doses) total spending Euro 66,671. It was possible to note that as the years of treatment increased the gap between of administrations widened. Results In the near future the ageing population will increasingly request good treatment of AMD. The latest ISTAT data indicate an increase in population over the age of 65 years (18.5% of the population). Evaluating the incidence of AMD at 3.68% (EUREYE study) of which 20% is wet AMD forces us to consider the need to revise our opinion of the sustainability of the treatment of the disease. No conflict of interest." @default.
• W1963955499 created "2016-06-24" @default.
• W1963955499 creator A5049065050 @default.
• W1963955499 creator A5050692116 @default.
• W1963955499 creator A5051906841 @default.
• W1963955499 date "2013-03-01" @default.
• W1963955499 modified "2023-09-26" @default.
• W1963955499 title "DSL-015 Financial Impact of Anti-VEGF in Ophthalmology" @default.
• W1963955499 doi "https://doi.org/10.1136/ejhpharm-2013-000276.258" @default.
• W1963955499 hasPublicationYear "2013" @default.
• W1963955499 type Work @default.
• W1963955499 sameAs 1963955499 @default.
• W1963955499 citedByCount "0" @default.
• W1963955499 crossrefType "journal-article" @default.
• W1963955499 hasAuthorship W1963955499A5049065050 @default.
• W1963955499 hasAuthorship W1963955499A5050692116 @default.
• W1963955499 hasAuthorship W1963955499A5051906841 @default.
• W1963955499 hasBestOaLocation W19639554991 @default.
• W1963955499 hasConcept C118487528 @default.
• W1963955499 hasConcept C126322002 @default.
• W1963955499 hasConcept C2776403814 @default.
• W1963955499 hasConcept C2776694085 @default.
• W1963955499 hasConcept C2777512022 @default.
• W1963955499 hasConcept C2777802072 @default.
• W1963955499 hasConcept C2781100027 @default.
• W1963955499 hasConcept C71924100 @default.
• W1963955499 hasConceptScore W1963955499C118487528 @default.
• W1963955499 hasConceptScore W1963955499C126322002 @default.
• W1963955499 hasConceptScore W1963955499C2776403814 @default.
• W1963955499 hasConceptScore W1963955499C2776694085 @default.
• W1963955499 hasConceptScore W1963955499C2777512022 @default.
• W1963955499 hasConceptScore W1963955499C2777802072 @default.
• W1963955499 hasConceptScore W1963955499C2781100027 @default.
• W1963955499 hasConceptScore W1963955499C71924100 @default.
• W1963955499 hasLocation W19639554991 @default.
• W1963955499 hasOpenAccess W1963955499 @default.
• W1963955499 hasPrimaryLocation W19639554991 @default.
• W1963955499 hasRelatedWork W1976851897 @default.
• W1963955499 hasRelatedWork W2063844644 @default.
• W1963955499 hasRelatedWork W2154929668 @default.
• W1963955499 hasRelatedWork W2316622455 @default.
• W1963955499 hasRelatedWork W2322211075 @default.
• W1963955499 hasRelatedWork W2341535407 @default.
• W1963955499 hasRelatedWork W2520129936 @default.
• W1963955499 hasRelatedWork W2527826246 @default.
• W1963955499 hasRelatedWork W2602825505 @default.
• W1963955499 hasRelatedWork W2761060818 @default.
• W1963955499 hasRelatedWork W2772251042 @default.
• W1963955499 hasRelatedWork W2772879023 @default.
• W1963955499 hasRelatedWork W2804532233 @default.
• W1963955499 hasRelatedWork W2911623215 @default.
• W1963955499 hasRelatedWork W2983875560 @default.
• W1963955499 hasRelatedWork W3007231415 @default.
• W1963955499 hasRelatedWork W3035509592 @default.
• W1963955499 hasRelatedWork W3042912176 @default.
• W1963955499 hasRelatedWork W3138976736 @default.
• W1963955499 hasRelatedWork W3207043302 @default.
• W1963955499 isParatext "false" @default.
• W1963955499 isRetracted "false" @default.
• W1963955499 magId "1963955499" @default.
• W1963955499 workType "article" @default.